Case Report
Bortezomib Use for a Critically Ill Patient with Angioimmunoblastic T-Cell Lymphoma
Table 1
Previous case reports of bortezomib use in angioimmunoblastic T-cell lymphoma.
| ā | Age/Sex | Treatment | Response | Duration of effectiveness | Reference |
| case1 | 63/Female | Bortezomib and dexamethasone | Lymphadenopathies reduced in size | 4 months | 14 |
| case2 | 76/Female | Bortezomib, mitoxantrone, and dexamethasone | Disappearance of lymphadenopathy | 18 months | 15 |
|
|